Comparative analysis of IgG Responses to recombinant Qβ phage displayed MSP3 and UB05 in Dual HIV-malaria infected adults living in areas differing in Malaria transmission intensities

Immunoglobulin G specific responses against Plasmodium falciparum merozoite antigens such as the merozoite surface protein 3 (MSP3) and UB05 are known to play critical roles in parasitemia control and protection from symptomatic illness. However when there is intense perennial malaria transmission coupled with concurrent infection with the human immunodeficiency virus type 1 (HIV), knowledge of IgG antibody response profiles is limited. In this study we assessed the impact of dual HIV-Malaria infections on IgG subclass responses to MSP3 (QβMSP3) and UB05 (QβUB05) in individuals living in two areas of Cameroon differing in transmission intensity. We observed differences in antigen specific IgG and IgG subclass responses which was dependent upon the antigen type, malaria transmission intensity, HIV infection, malaria infection and dual HIV-malaria infections. Individuals living in high malaria transmission areas irrespective of HIV or malaria status had significantly higher IgG responses to both antigens (P=0.0001 for QβMSP3, P=0.0001 for QβUB05) than their counterpart from low transmission areas. When dual HIV-Malaria infection is considered significantly higher QβMSP3 specific IgG1 (P=0.0001) and IgG3 (P=0.04) responses in double negative individuals was associated with protection against malaria in low transmission areas. Superior QβUBO5 specific IgG1 responses (P=0.0001) in double negative individuals were associated with protection in high transmission areas in contrast to significantly higher IgG3 responses to QβUB05 (P=0.0001) which were more relevant to protection in low malaria transmission areas in the same population. Thus, understanding immune responses to QβUB05 and QβMSP3 could facilitate the development of immunotherapeutic strategies suitable for areas differing in malaria transmission intensity.

[1]  G. Nchinda,et al.  Filaria specific antibody response profiling in plasma from anti-retroviral naïve Loa loa microfilaraemic HIV-1 infected people , 2018, BMC Infectious Diseases.

[2]  S. Billong,et al.  Prevalence and risk factors to HIV-infection amongst health care workers within public and private health facilities in Cameroon , 2018, The Pan African medical journal.

[3]  S. Ghogomu,et al.  Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB05‐09 antigen could be a malaria vaccine candidate , 2018, Parasite immunology.

[4]  G. Nchinda,et al.  Phenotypic characterization of regulatory T cells from antiretroviral‐naive HIV‐1‐infected people , 2017, Immunology.

[5]  G. Nchinda,et al.  The Effect of Antiretroviral Naïve HIV-1 Infection on the Ability of Natural Killer Cells to Produce IFN-γ upon Exposure to Plasmodium falciparum-Infected Erythrocytes , 2017, Biomedicine Hub.

[6]  F. Osier,et al.  Changes in Malaria Epidemiology in Africa and New Challenges for Elimination , 2016, Trends in parasitology.

[7]  A. Njunda,et al.  The prevalence of malaria in people living with HIV in Yaounde, Cameroon , 2016, BMC Public Health.

[8]  Arlo Z. Randall,et al.  Plasmodium falciparum Protein Microarray Antibody Profiles Correlate With Protection From Symptomatic Malaria in Kenya. , 2015, The Journal of infectious diseases.

[9]  M. Laurens,et al.  Vaccines against malaria. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  K. Badu,et al.  The prevalence of malaria among HIV seropositive individuals and the impact of the co- infection on their hemoglobin levels , 2015, Annals of Clinical Microbiology and Antimicrobials.

[11]  O. Doumbo,et al.  Protection of Malian children from clinical malaria is associated with recognition of multiple antigens , 2015, Malaria Journal.

[12]  D. Masiga,et al.  High-resolution melting analysis reveals low Plasmodium parasitaemia infections among microscopically negative febrile patients in western Kenya , 2014, Malaria Journal.

[13]  S. Aller,et al.  In Vitro Evolution and Affinity-Maturation with Coliphage Qβ Display , 2014, PloS one.

[14]  J. Kublin,et al.  HIV-1 infection and antibodies to Plasmodium falciparum in adults. , 2014, The Journal of infectious diseases.

[15]  M. Bouyou-Akotet,et al.  Falciparum Malaria as an Emerging Cause of Fever in Adults Living in Gabon, Central Africa , 2014, BioMed research international.

[16]  B. Lowe,et al.  A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria☆ , 2013, Vaccine.

[17]  M. Christiansen,et al.  The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas. , 2013, The Journal of infectious diseases.

[18]  Miles P. Davenport,et al.  The Dynamics of Naturally Acquired Immunity to Plasmodium falciparum Infection , 2012, PLoS Comput. Biol..

[19]  Kevin Marsh,et al.  Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. , 2012, The Journal of clinical investigation.

[20]  J. Ferro,et al.  Prevalence and clinical features of HIV and malaria co-infection in hospitalized adults in Beira, Mozambique , 2012, Malaria Journal.

[21]  C. John,et al.  Antibodies to Plasmodium falciparum Erythrocyte-binding Antigen-175 are Associated With Protection From Clinical Malaria , 2011, The Pediatric infectious disease journal.

[22]  S. Cousens,et al.  Protection against malaria by MSP3 candidate vaccine. , 2011, The New England journal of medicine.

[23]  O. Doumbo,et al.  A field trial to assess a blood-stage malaria vaccine. , 2011, The New England journal of medicine.

[24]  Matthew A. Kayala,et al.  Sterile Protective Immunity to Malaria is Associated with a Panel of Novel P. falciparum Antigens* , 2011, Molecular & Cellular Proteomics.

[25]  D. Doolan,et al.  Malaria vaccine design: immunological considerations. , 2010, Immunity.

[26]  A. Cowman,et al.  Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  T. Theander,et al.  Age-dependent association between IgG2 and IgG3 subclasses to Pf332-C231 antigen and protection from malaria, and induction of protective antibodies by sub-patent malaria infections, in Daraweesh. , 2010, Vaccine.

[28]  Jack S. Richards,et al.  The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis , 2010, PLoS medicine.

[29]  R. Noor,et al.  Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months , 2009, Malaria Journal.

[30]  P. Druilhe,et al.  Toward the Rational Design of a Malaria Vaccine Construct Using the MSP3 Family as an Example: Contribution of Immunogenicity Studies in Models , 2009, Infection and Immunity.

[31]  P. Gilson,et al.  Immunoglobulin G Subclass-Specific Responses against Plasmodium falciparum Merozoite Antigens Are Associated with Control of Parasitemia and Protection from Symptomatic Illness , 2009, Infection and Immunity.

[32]  C. Rogier,et al.  Long-Term Clinical Protection from Falciparum Malaria Is Strongly Associated with IgG3 Antibodies to Merozoite Surface Protein 3 , 2007, PLoS medicine.

[33]  Hong Zhou,et al.  In Immunization with Plasmodium falciparum Apical Membrane Antigen 1, the Specificity of Antibodies Depends on the Species Immunized , 2007, Infection and Immunity.

[34]  A. Nasr,et al.  Fc gamma Receptor IIa (CD32) Polymorphism and Antibody responses to Asexual Blood‐stage Antigens of Plasmodium falciparum Malaria in Sudanese Patients , 2007, Scandinavian journal of immunology.

[35]  Andrea Crisanti,et al.  Profiling the antibody immune response against blood stage malaria vaccine candidates. , 2007, Clinical chemistry.

[36]  Aditi Gupta,et al.  Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Theisen,et al.  Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. , 2004, The Journal of infectious diseases.

[38]  F. Ntoumi,et al.  Sickle cell trait carriage: imbalanced distribution of IgG subclass antibodies reactive to Plasmodium falciparum family-specific MSP2 peptides in serum samples from Gabonese children. , 2002, Immunology letters.

[39]  R. Anders,et al.  Specificity of the Protective Antibody Response to Apical Membrane Antigen 1 , 2001, Infection and Immunity.

[40]  S. Hoffman,et al.  Repeated infection of Aotus monkeys with Plasmodium falciparum induces protection against subsequent challenge with homologous and heterologous strains of parasite. , 2000, The American journal of tropical medicine and hygiene.

[41]  F. Fumoux,et al.  High Immunoglobulin G2 (IgG2) and Low IgG4 Levels Are Associated with Human Resistance to Plasmodium falciparum Malaria , 2000, Infection and Immunity.

[42]  F. Lunel,et al.  Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages , 1995, The Journal of Experimental Medicine.

[43]  A. Sabchareon,et al.  Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes , 1990, The Journal of experimental medicine.

[44]  G. Nchinda,et al.  Surface Engineering of the RNA Coliphage Qβ to Display Plasmodium Falciparum Derived Asexual Blood Stage Antigens UB05 and Merozoite Surface Protein 3 , 2018 .

[45]  A. Amambua-Ngwa,et al.  Isolation and expression of UB05, a Plasmodium falciparum antigen recognised by antibodies from semi-immune adults in a high transmission endemic area of the Cameroonian rainforest , 2009, Clinical chemistry and laboratory medicine.

[46]  S. Agnandji,et al.  Interleukin-21 is associated with IgG1 and IgG3 antibodies to erythrocyte-binding antigen-175 peptide 4 of Plasmodium falciparum in Gabonese children with acute falciparum malaria. , 2008, European cytokine network.

[47]  P. Rosenthal,et al.  Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. , 2006, The Journal of infectious diseases.

[48]  A. Tartar,et al.  Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. , 1994, Blood.

[49]  W H TALIAFERRO,et al.  Acquired immunity in malaria. , 1948, Abstracts. International Congress on Tropical Medicine and Malaria.